UNASSIGNED: Tumor diagnostics are based on histomorphology, immunohistochemistry and molecular pathological analysis of mutations, translocations and amplifications which are of diagnostic, prognostic and/or predictive value. In recent decades only histomorphology was used to classify @entity2 as either small ( @entity4153 ) or @entity1149 ( @entity1149 ), although @entity1149 was further subdivided in different entities; however, as no specific therapy options were available classification of specific subtypes was not clinically meaningful. This fundamentally changed with the discovery of specific molecular alterations in @entity420 ( @entity420 ), e.g. mutations in @entity984 , @entity470 and @entity817 or translocations of the @entity7041 and @entity31082 gene loci, which now form the basis of targeted therapies and have led to a significantly improved @entity1 outcome. The diagnostic, prognostic and predictive value of imaging, morphological, immunohistochemical and molecular characteristics as well as their interaction were systematically assessed in a large cohort with available clinical data including @entity1 survival. Specific and sensitive diagnostic markers and marker panels were defined and diagnostic test algorithms for predictive biomarker assessment were optimized. It was demonstrated that the semi-quantitative assessment of @entity420 growth patterns is a stage-independent predictor of survival and is reproducibly applicable in the routine setting. Specific histomorphological characteristics correlated with computed tomography (CT) imaging features and thus allowed an improved interdisciplinary classification, especially in the preoperative or palliative setting. Moreover, specific molecular characteristics, for example @entity817 mutations and the proliferation index (Ki-67) were identified as clinically relevant prognosticators. Comprehensive clinical, morphological, immunohistochemical and molecular assessment of NSCLCs allow an optimized @entity1 stratification. Respective algorithms now form the backbone of the 2015 @entity2 World Health Organization (WHO) classification.

[Diagnosis, prognosis, and prediction of XXXX : Importance of morphology, immunohistochemistry and molecular pathology].

@entity7041 :: ('238', 'Gene') :: ['ALK'] @entity1 :: ('9606', 'Species') :: ['patient'] @entity4153 :: ('MESH:D018288', 'Disease') :: ['SCLC'] @entity984 :: ('3845', 'Gene') :: ['KRAS'] @entity470 :: ('1956', 'Gene') :: ['EGFR'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer'] @entity31082 :: ('6098', 'Gene') :: ['ROS1'] @entity817 :: ('673', 'Gene') :: ['BRAF'] @entity420 :: ('MESH:D000230', 'Disease') :: ['ADC', 'adenocarcinoma']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
